Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Scientists are getting our robotic explorers ready to help send humans to Mars - 2Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- 3Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- 4How did Hugh Jackman nail his latest role? Sequins, tighty-whities and embracing 'zero embarrassment.'
- 510 Asian Countries Perfect for Solo Female Travelers
- The Best Web-based Courses for Ability Advancement
- Web designers for Independent ventures
- Figure out how to Consolidate a Brain science Certificate with Social Work
- Vote in favor of your Number one Sort of Cap
- Pick Your Number one Sort Of Music
- In these U.S. groups, deaths now exceed births. What’s happening?
- Grasping the Elements of Medical caretaker Pay rates: Factors That Shape Your Pay
- People are getting their news from AI – and it’s altering their views
- Investigating Inside Plan and Home Style: Change Your Residing Space
